Amaç: Milyonlarca ölüme neden olan koronavirüs hastalığı-2019'un [coronavirus disease-2019 (COVID-19)] kesin tedavisi henüz bilinmediğinden, mortalite açısından yüksek riskli grupların ve prognoza etki eden faktörlerin belirlenmesi önemlidir. Çalışmamızda, hastaneye yatırılarak izlenen COVID-19 olgularının demografik, klinik ve laboratuvar verilerinin değerlendirilmesi; prognoza ve mortaliteye etkili faktörlerin saptanması amaçlandı. Gereç ve Yöntemler: Pandemi servisi veya yoğun bakım ünitesinde yatarak tedavi almış, polimeraz zincir reaksiyonu testi pozitif hastaların demografik, klinik ve laboratuvar özellikleri retrospektif olarak incelendi. Pnömoni şiddeti, yatış süresi, mortalite verileri incelendi. Mortalite ilişkili faktörler değerlendirildi. Bulgular: Çalışmadaki 165 hastanın yaş ortalaması 59±16 (%58 erkek) yıldı. Hastaların %57'si hiç sigara içmemişken, %43'ü eski veya aktif içiciydi. En sık görülen komorbid hastalıklar hipertansiyon (%50,3) ve diyabetti (%25,5). İleri yaş, erkek cinsiyet, sigara kullanımı, yüksek modifiye Charlson Komorbidite İndeksi, geliş oksijen satürasyon düşüklüğü, yüksek tomografi skoru ve uzun yatış süresinin mortaliteyi öngördüğü belirlendi. Nötrofil, nötrofil lenfosit oranı, üre, laktat dehidrogenaz, C-reaktif protein (CRP), ferritin yüksekliği ve albümin düşüklüğü ile mortalite arasında pozitif korelasyon izlendi. Nötrofil değerleri 4.000/μL ve üzerinde olması, CRP düzeyinin 50 mg/L'nin üzerinde olması ve ferritin değerinin 700 ng/mL'nin üzerinde olması mortalite riskinde sırasıyla 9 kat 5,7 kat ve 3,8 kat artışa neden olmaktadır. Takipte, tedavisine steroid eklenmek zorunda kalınan hastaların mortalitesinin daha fazla olduğu saptanmıştır. Sonuç: Komorbiditesi yüksek, yaşlı, erkek, başlangıçta oksijen satürasyonu düşük, tomografi skoru yüksek ve laboratuvar parametreleri bozulmuş hastalarda mortalite daha fazladır. İlk tedaviye yanıtsızlık, takipte steroid tedavisi gereksinimi, yoğun bakım ihtiyacı ve uzun süreli yatış diğer kötü prognostik faktörlerdir.
Anahtar Kelimeler: COVID-19; modifiye Charlson Komorbidite İndeksi; prognoz; mortalite
Objective: It is critical to identify factors affecting prognosis in coronavirus disease-2019 (COVID-19). In this study, we aimed to evaluate the demographic, clinical and laboratory data of hospitalized patients with COVID-19 and to determine the factors affecting the prognosis and survival. Material and Methods: Demographic, clinical and laboratory findings of polymerase chain reaction-positive inpatients were evaluated and recorded retrospectively. Pneumonia severity, length of hospital stay, and mortality data were analyzed. Results: The mean age of the 165 patients was 59±16 (58% male) years. While 57% of the patients were non-smokers, 43% were quitters or smokers. The most common comorbid diseases were hypertension(50,3%) and diabetes (25,5%). Advanced age, male gender, smoking, high modified Charlson Comorbidity Index, low oxygen saturation, high computed tomography (CT) score at admission was related to mortality. There was a positive correlation between mortality and high neutrophil counts, neutrophil lymphocyte ratio, urea, lactate dehydrogenase, C-reactive protein (CRP), ferritin and low albumin levels. When the neutrophil counts are ≥4,000/μL, there is 9-fold increase in the risk of mortality. CRP levels >50 mg/L causes a 5.7-fold, and ferritin values >700 ng/mL causes a 3.8-fold increase in the mortality risk. Mortality was higher in patients who need add-on steroid theraphy during follow-up. Conclusion: The mortality rate is higher in patients with COVID-19 who are elderly, male and who have manycomorbidities, low oxygen saturation, high CT score and impaired laboratory parameters. Other factors associated with poor prognosis are unresponsiveness to first treatment, long-term hospitalization and the need for add-on steroids or intensive care admission.
Keywords: COVID-19; modified Charlson Index; prognosis; mortality
- Worldometers [Internet]. [Cited: January 8, 2022]. COVID-19 coronavirus pandemic. Available from: [Link]
- Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;23(5):1416-24. [Crossref] [PubMed]
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. [Crossref] [PubMed]
- RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. [Crossref] [PubMed] [PMC]
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. [Crossref] [PubMed]
- Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35(3):181-200. [Crossref] [PubMed]
- Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro L, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol. 2020;30(12):6808-17. [Crossref] [PubMed] [PMC]
- T.C Sağlık Bakanlığı [İnternet]. © 2022 T.C. Sağlık Bakanlığı. [Erişim tarihi: 09.04.2020]. Erişkin Hasta Tedavi Rehberi. Erişim linki: [Link]
- Qian J, Zhao L, Ye RZ, Li XJ, Liu YL. Age-dependent gender differences in COVID-19 in Mainland China: Comparative Study. Clin Infect Dis. 2020;71(9):2488-94. [Crossref] [PubMed] [PMC]
- Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020;11(1):53. [Crossref] [PubMed] [PMC]
- Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. 2020;14(4):283-7. [Crossref] [PubMed] [PMC]
- Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215. [Crossref] [PubMed] [PMC]
- Wang AL, Zhong X, Hurd YL. Comorbidity and sociodemographic determinants in COVID-19 mortality in an US urban healthcare system. MedRxiv. 2020 Jan 1. [Crossref]
- Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38. [Crossref] [PubMed] [PMC]
- Shao M, Li X, Liu F, Tian T, Luo J, Yang Y. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: a systematic review and meta-analysis of 40 studies and 24,527 patients. Pharmacol Res. 2020;161:105107. [Crossref] [PubMed] [PMC]
- Singh J, Malik P, Patel N, Pothuru S, Israni A, Chakinala RC, et al. Kidney disease and COVID-19 disease severity-systematic review and meta-analysis. Clin Exp Med. 2022;22(1):125-35. [Crossref] [PubMed] [PMC]
- Hu Y, Zhan C, Chen C, Ai T, Xia L. Chest CT findings related to mortality of patients with COVID-19: a retrospective case-series study. PLoS One. 2020;15(8):e0237302. [Crossref] [PubMed] [PMC]
- Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-8. [Crossref] [PubMed]
- Henry B, Cheruiyot I, Vikse J, Mutua V, Kipkorir V, Benoit J, et al. Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis. Acta Biomed. 2020;91(3):e2020008. [PubMed] [PMC]
- Ziadi A, Hachimi A, Admou B, Hazime R, Brahim I, Douirek F, et al. Lymphopenia in critically ill COVID-19 patients: a predictor factor of severity and mortality. Int J Lab Hematol. 2021;43(1):e38-40. [Crossref] [PubMed] [PMC]
- Valerio L, Ferrazzi P, Sacco C, Ruf W, Kucher N, Konstantinides SV, et al; Humanitas COVID-19 Task Force. Course of D-dimer and c-reactive protein levels in survivors and nonsurvivors with COVID-19 pneumonia: a retrospective analysis of 577 patients. Thromb Haemost. 2021;121(1):98-101. [Crossref] [PubMed] [PMC]
- El-Shabrawy M, Alsadik ME, El-Shafei M, Abdelmoaty AA, Alazzouni AS, Esawy MM, et al. Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. Egypt J Bronchol. 2021;15(1):1-7. [Crossref] [PMC]
- Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175. [Crossref] [PubMed] [PMC]
- American College of Cardiology [Internet]. © 2020 American College of Cardiology Foundation. [Cited: March 29, 2020]. Ventricular Arrhythmia Risk Due to HydroxychloroquineAzithromycin Treatment For COVID-19. Available from: [Link]
- RECOVERY [Internet]. © 2020 Nuffield Department of Population Health. [Cited: January 26, 2020]. Randomised Evaluation for COVID-19 Therapy. Available from: [Link]
- Özlüşen B, Kozan Ş, Akcan RE, Kalender M, Yaprak D, Peltek İB, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021;40(12):2575-83. [Crossref] [PubMed] [PMC]
.: Process List